Johnson & Johnson agreed to acquire Ollin Biosciences for up to $3.3 billion, adding a late-stage ophthalmology bispecific antibody to its pipeline. The deal also includes support from Blackstone Life Sciences for Phase 3 development of OLN324, as J&J frames the transaction as a potential growth platform in retinal disease. The acquisition signals continued consolidation around late-stage retinal assets, particularly those positioned to compete in markets served by approved drugs such as Roche’s Vabysmo. J&J said combining Ollin’s science with its scale could accelerate clinical progress toward preserving and restoring vision. The transaction further underscores how capital and portfolio strategy are shifting toward dense, high-value retina franchises.
Get the Daily Brief